Longitudinal Coverage With Evidence Development Study on Micra Leadless Pacemakers

Overview

The primary purpose of the study is to meet the CMS mandated Coverage with Evidence Development requirement in the National Coverage Determination for Leadless Pacemakers as they apply to Medtronic Micra devices. The study uses administrative claims data of the Medicare population implanted with single-chamber ventricular pacemakers. Patients are enrolled through submission of claims or encounter data to CMS.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: June 2027

Detailed Description

Micra CED study is a study of the Medicare beneficiary population implanted with single-chamber ventricular pacemakers, and will be executed by analyzing administrative claims data. The study consists of two primary objectives: estimate the: (1) acute overall complication rate and (2) the 2-year survival rate of patients implanted with a Micra leadless pacemaker. As part of the secondary objectives of the study, a comparative analysis of Micra leadless pacemakers to single-chamber ventricular transvenous pacemakers will be conducted. The analysis will be in CMS claims data and is subject to a central IRB. However, individual hospitals are not engaged in research and local IRB oversight is not necessary.

Arms, Groups and Cohorts

  • Micra leadless pacemaker therapy
    • All Medicare patients implanted with Micra leadless pacemaker system
  • Single Chamber Transvenous pacemaker
    • All Medicare patients implanted with full system (e.g. lead and generator) single- chamber ventricular transvenous pacemakers

Clinical Trial Outcome Measures

Primary Measures

  • Acute complication rate
    • Time Frame: 30 days
    • Single-chamber ventricular pacemaker system and/or procedure related complications at 30 days. Acute complications include embolism/thrombosis, event at the puncture site, cardiac effusion/perforation, device-related complication, or other complications following the implantation of a single-chamber ventricular pacemaker system. Subjects’ administrative claims data will be reviewed to determine the occurrence of an acute complication.
  • The 2-year survival rate of patients implanted with a Micra leadless pacemaker
    • Time Frame: 2 years
    • Estimate the 2-year survival rate of patients implanted with a Micra leadless pacemaker

Secondary Measures

  • Chronic complication rate
    • Time Frame: 6 months
    • Chronic complications are a subset of acute complications that may also occur within six months following the implantation of a single-chamber ventricular pacemaker. Single-chamber ventricular pacemaker system and/or procedure related complications at six months. Subjects’ administrative claims data will be reviewed to determine the occurrence of a chronic complication.
  • Device-related re-intervention rates
    • Time Frame: 2 years
    • Device-related re-interventions are procedures associated with the insertion/replacement, revision, or removal of either a leadless or transvenous pacemaker system or components following the index implantation of a single-chamber ventricular pacemaker. Device-related re-intervention rates will be reported at six month intervals for two years following the index implantation of a single-chamber ventricular pacemaker. Subjects’ administrative claims data will be reviewed to determine the occurrence of a device-related re-intervention

Participating in This Clinical Trial

Inclusion Criteria

• Medicare beneficiaries implanted with a leadless pacemaker (CPT 0387T or 33274 or ICD-10 PCS 02HK3NZ) on or after the study start date will be included in the study. or • Medicare beneficiaries with implanted with a full system single-chamber ventricular transvenous pacemaker (CPT 33207 or ICD-10 PCS 0JH605Z or 0JH604Z and 02HK3JZ) on or after the study start date. Exclusion Criteria:

• None

Gender Eligibility: All

Minimum Age: N/A

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Medtronic
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Mikhael El Chami, MD, Principal Investigator, Emory University

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.